Literature DB >> 8528696

5-HT1A, GABAB, and pirenzepine-insensitive muscarinic receptors are functionally coupled to distinct pools of the same kind of G proteins in rat hippocampus.

Y Odagaki1, K Fuxe.   

Abstract

In order to probe the interaction between the neurotransmitter receptors and guanine nucleotide-binding regulatory (G) proteins in rat hippocampus, the high-affinity GTPase activity stimulated by 5-hydroxytryptamine (5-HT), gamma-aminobutyric acid (GABA), carbachol (CCh), and dopamine (DA) has been investigated, focusing on the additivity among the effects of these agonists at their maximally effective concentrations. There were simple additive relationships among 5-HT-, GABA-, and CCh-stimulated activities. As 5-HT, GABA-, and CCh-stimulated high-affinity GTPase activities are mediated by the 5-HT1A, GABAB, and pirenzepine-insensitive muscarinic receptors, respectively, the additive effects indicate that these three receptors are independently coupled to distinct pools of G proteins. In contrast, an apparent lack of additivity was seen between 5-HT- and DA-stimulated activities. This phenomenon was likely due to an activation of the common 5-HT1A receptor-mediated signalling by DA as well as 5-HT, since the DA-sensitive increment of the activity was potently inhibited by the 5-HT1 receptor antagonist methiothepin, but not by the DA D2 receptor antagonist raclopride.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8528696     DOI: 10.1016/0006-8993(95)00576-c

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  2 in total

1.  Functional coupling between A1 adenosine receptors and G-proteins in rat hippocampal membranes assessed by high-affinity GTPase activity.

Authors:  Y Odagaki; K Fuxe
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

2.  Modulation of midbrain dopamine neurotransmission by serotonin, a versatile interaction between neurotransmitters and significance for antipsychotic drug action.

Authors:  J E Olijslagers; T R Werkman; A C McCreary; C G Kruse; W J Wadman
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.